“Through his tremendous work, Dr. Palevsky has helped reduce the risk of acute kidney injury and increase the likelihood of recovery from it, for many thousands of patients,” said Dr. Michael Choi, president and chair of the NKF Scientific Advisory Board.
Palevsky’s research focuses primarily on acute kidney injury and critical care nephrology. He was the study chair of the VA/NIH Acute Renal Failure Trial Network, a study evaluating the intensity of renal replacement therapy in critically ill patients with acute kidney injury. He currently serves as co-chair of the PRESERVE trial, which is studying the comparative effectiveness of saline and bicarbonate and the efficacy of N-acetylcysteine in preventing kidney damage following angiography. Palevsky has published more than 200 original articles, reviews and book chapters, and has served as an editor for clinical journals focused on nephrology.
The Dr. J. Michael Lazarus Distinguished Award was established to honor Dr. Lazarus for his major contributions to the clinical science and care of dialysis patients, and to recognize individuals whose research has yielded novel insights related to renal replacement therapy.
Dr. Paul Palevsky has been selected to receive the Dr. J. Michael Lazarus Distinguished Award from the National Kidney Foundation (NKF) during the organization’s upcoming Spring Clinical Meetings in Orlando. He is a professor of medicine and clinical and translational science in the Renal-Electrolyte Division of the Department of Medicine at the University of Pittsburgh School of Medicine. He also serves as chief of the VA Pittsburgh Healthcare System’s Renal Section.
